Redirecting to https://apnews.com/press-release/globenewswire-mobile/blossomhill-therapeutics-announces-84-million-financing-to-accelerate-clinical-stage-pipeline-of-intelligently-designed-cancer-medicines-including-first-in-class-macrocyclic-omni-egfrtm-inhibitor-for-nsclc-59a4c4c71ff9d991501f3a5c66429733